Anasayfa » News » Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPC

Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPC

Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPC
You May Be Interested In:2025 Stanley Cup first-round betting guide: Best bets and Conn Smythe predictions



(MedPage Today) — SAN FRANCISCO — The addition of radionuclide therapy with 177Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with metastatic castration-resistant prostate cancer (CRPC), according…

share Paylaş facebook pinterest whatsapp x print

Similar Content

Te Whatu Ora proposes to ax a third of data, digital roles
Te Whatu Ora proposes to axe a third of data, digital roles December 2, 2024
PBM Private Labeling Boosts Biosimilars, Raises Concerns
PBM Private Labeling Boosts Biosimilars, Raises Concerns April 3, 2025
Tips from a small hospital CIO to succeed with legacy vendors
Tips from a small hospital CIO to succeed with legacy vendors December 3, 2024
A photo of two voters — a man in the back and a woman with a baby carrier in the front.
Many Voters Backed Abortion Rights and Donald Trump, a Challenge for Democrats – KFF Health News November 8, 2024
A health insurance claim form on a clipboard. A black pen rests on top.
Covered California Hits Record Enrollment, but Key Subsidies in Jeopardy – KFF Health News January 23, 2025
Allergy medications: Know your options
Eye twitching January 18, 2025
▲
The News Link | © 2025 | News